- November 2014
Carl June on the efficacy of CAR-T cells in treating leukaemia.
- October 2014
News from ESMO 2014 with Solange Peters and Alexander Eggermont.
- September 2014
Discussing how healthcare systems can meet the needs of cancer survivors.
- July/August 2014
Sophie Postel-Vinay on new recommendations for phase 1 trials.
- June 2014
Hans Clevers on important research into stem cells in normal gut tissue.
- May 2014
Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
- April 2014
Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
- March 2014
The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
- February 2014
Charles Swanton on a study that maps genetic changes in cancers over time.
- January 2014
Presidents of various cancer societies make predictions for the coming year.
EJC News Focus – December 2013
Precision diagnostics: great potential but is Europe falling behind?
Molecular diagnostics are becoming increasingly important as oncology moves from an era of stratification to personalisation; precision medicine will develop hand in hand with new diagnostic techniques. But according to ESMO President Martine Piccart, there is 'a high unmet need' for molecular diagnostics in Europe. Pharmaceutical companies have little incentive to invest in their development, she says, mainly because of the lack of a clear regulatory path, but also because of the reluctance among oncologists to use available tests.
The groundbreaking SHIVA trial is an excellent example of the central role of the new diagnostics: patients' treatment is determined only by the molecular profile of their tumour, without reference to its anatomical location. Christophe Le Tourneau (Institut Curie, Paris) presented early data at the European Cancer Conference (Amsterdam, Sept 27 – Oct 1, 2013), which hints at the promise of this approach.
In this month's EJC News Focus, Martine Piccart outlines to Helen Saul the cultural and practical changes that will be necessary to drive the development of diagnostics in Europe, and Christophe Le Tourneau demonstrates how these new precision diagnostics could drive progress in oncology.